Pan-solid tumor driver gene mutation detection covers companion diagnostic genes approved by the FDA and recommended by NCCN Guidelines. This assay includes 56 genes associated with treatment and prognosis, covering 3,000 COSMIC variants, and delivers cost-effective, high-sensitivity, high-throughput testing for solid tumor tissue and circulating cell-free DNA samples.
Cancer is a complex polygenic disorder resulting from stepwise accumulation of genetic mutations. Alterations in growth-regulating genes cause uncontrolled cell proliferation and differentiation, driving malignant tumor development.

DNA:Detects single nucleotide variants (SNVs) and small insertion-deletion variants (InDels) across 50 genes.
RNA:Detects 6 gene fusions (ROS1, ALK, RET, NTRK1, NTRK2, NTRK3) and MET exon 14 skipping mutations.
AMP:HER2 and MET gene amplification status.
Applicable to patients with a variety of solid tumors and select hematological malignancies. This assay primarily evaluates drug sensitivity and prognosis for cancer patients receiving targeted therapy, assisting clinicians in selecting appropriate targeted agents and enabling comprehensive guidance on systemic treatment strategies. It also delivers partial hereditary-related genomic information to assess familial cancer risks.
1. Nucleic Acid Extraction
2. Library Preparation
3. Sequencing
4. One-stop Data Analysis
5. Report Generation
闽公网安备35021202000745